{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:20:50Z","timestamp":1783693250606,"version":"3.55.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81100386"],"award-info":[{"award-number":["81100386"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.molimm.2026.05.013","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T03:43:46Z","timestamp":1780803826000},"page":"24-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Restoration of Treg function and polarization of M2 macrophages by tofacitinib to alleviate sarcoidosis through the mediation of the JAK3\/STAT5 pathway"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5240-9449","authenticated-orcid":false,"given":"Ting","family":"Sheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8366-7887","authenticated-orcid":false,"given":"Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molimm.2026.05.013_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104392","article-title":"The new entries in the therapeutic armamentarium: the small molecule JAK inhibitors","volume":"147","author":"Bechman","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"6","key":"10.1016\/j.molimm.2026.05.013_bib2","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/annrheumdis-2014-206028","article-title":"The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis","volume":"74","author":"Boyle","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.molimm.2026.05.013_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00437","article-title":"Granuloma formation in pulmonary sarcoidosis","volume":"4","author":"Broos","year":"2013","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2026.05.013_bib4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41420-025-02459-z","article-title":"Immunotherapy for autoimmune encephalitis","volume":"11","author":"Cheng","year":"2025","journal-title":"Cell. Death Discov."},{"issue":"2","key":"10.1016\/j.molimm.2026.05.013_bib5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.revmed.2024.10.452","article-title":"JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases","volume":"46","author":"Chikhoune","year":"2025","journal-title":"Rev. Med. Interne"},{"issue":"3","key":"10.1016\/j.molimm.2026.05.013_bib6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/ibd\/izz213","article-title":"Tofacitinib reprograms human monocytes of IBD patients and healthy controls toward a more regulatory phenotype","volume":"26","author":"Cordes","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"issue":"26","key":"10.1016\/j.molimm.2026.05.013_bib7","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"New. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.molimm.2026.05.013_bib8","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jaad.2019.05.098","article-title":"Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare","volume":"82","author":"Damsky","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.molimm.2026.05.013_bib9","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/acr2.11112","article-title":"Treatment of Multiorgan Sarcoidosis With Tofacitinib","volume":"2","author":"Damsky","year":"2020","journal-title":"ACR Open. Rheumatol."},{"issue":"2","key":"10.1016\/j.molimm.2026.05.013_bib10","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/lary.31778","article-title":"JAK-inhibitor Tofacitinib in Severe Laryngeal Sarcoidosis: A Case Report","volume":"135","author":"Demir","year":"2025","journal-title":"Laryngoscope"},{"issue":"11","key":"10.1016\/j.molimm.2026.05.013_bib11","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.7150\/ijms.18838","article-title":"Extensively disturbance of regulatory T cells-Th17 cells balance in stage II pulmonary sarcoidosis","volume":"14","author":"Ding","year":"2017","journal-title":"Int. J. Med. Sci."},{"issue":"2","key":"10.1016\/j.molimm.2026.05.013_bib12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/thx.2010.140319","article-title":"Sarcoidosis is a Th1\/Th17 multisystem disorder","volume":"66","author":"Facco","year":"2011","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.molimm.2026.05.013_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00408-021-00436-8","article-title":"Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study","volume":"199","author":"Friedman","year":"2021","journal-title":"Lung"},{"issue":"1","key":"10.1016\/j.molimm.2026.05.013_bib14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","article-title":"Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors","volume":"75","author":"Gao","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.molimm.2026.05.013_bib15","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2026.05.013_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.molimm.2026.05.013_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/flgastro-2023-102400","article-title":"JAK inhibitors for inflammatory bowel disease: recent advances","volume":"15","author":"Honap","year":"2024","journal-title":"Frontline Gastroenterol."},{"issue":"2","key":"10.1016\/j.molimm.2026.05.013_bib18","first-page":"149","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis","volume":"16","author":"Hunninghake","year":"1999","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"issue":"21","key":"10.1016\/j.molimm.2026.05.013_bib19","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1056\/NEJMra071714","article-title":"Sarcoidosis","volume":"357","author":"Iannuzzi","year":"2007","journal-title":"New. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.molimm.2026.05.013_bib20","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1038\/s41598-022-06581-1","article-title":"Tofacitinib and metformin reduce the dermal thickness and fibrosis in mouse model of systemic sclerosis","volume":"12","author":"Karatas","year":"2022","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.molimm.2026.05.013_bib21","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaad.2020.10.016","article-title":"Tofacitinib for cutaneous and pulmonary sarcoidosis: A case series","volume":"84","author":"Kerkemeyer","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.molimm.2026.05.013_bib22","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3389\/fimmu.2020.01443","article-title":"Biomarkers in the Diagnosis and Prognosis of Sarcoidosis: Current Use and Future Prospects","volume":"11","author":"Kraaijvanger","year":"2020","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.molimm.2026.05.013_bib23","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.4049\/jimmunol.169.11.6610","article-title":"Rheumatoid arthritis synoviocyte survival is dependent on Stat3","volume":"169","author":"Krause","year":"2002","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.molimm.2026.05.013_bib24","first-page":"2167","article-title":"Abatacept and tofacitinib in refractory sarcoidosis: drug survival, safety, and treatment response","volume":"42","author":"Leffers","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.molimm.2026.05.013_bib25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"JAKS AND STATS: Biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.molimm.2026.05.013_bib26","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/JLB.5A0718-280RR","article-title":"Mapping mononuclear phagocytes in blood, lungs, and lymph nodes of sarcoidosis patients","volume":"105","author":"Lepzien","year":"2019","journal-title":"J. Leukoc. Biol."},{"issue":"9","key":"10.1016\/j.molimm.2026.05.013_bib27","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"STATs: Transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.molimm.2026.05.013_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/icb.2010.70","article-title":"Phenotypic and functional switch of macrophages induced by regulatory CD4(+)CD25(+) T cells in mice","volume":"89","author":"Liu","year":"2011","journal-title":"Immunol. Cell. Biol."},{"key":"10.1016\/j.molimm.2026.05.013_bib29","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3389\/fimmu.2020.01719","article-title":"Current Sarcoidosis Models and the Importance of Focusing on the Granuloma","volume":"11","author":"Locke","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.molimm.2026.05.013_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010783","article-title":"JAK3 (A573V) and JAK3 (M511I) mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3\/PD-L1 pathway","volume":"13","author":"Lou","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.molimm.2026.05.013_bib31","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.34329","article-title":"The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells","volume":"64","author":"Maeshima","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.molimm.2026.05.013_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf076","article-title":"Differential effects of tofacitinib on macrophage activation contribute to lack of response in ulcerative colitis patients","author":"Melon-Ardanaz","year":"2025","journal-title":"J. Crohns Colitis"},{"issue":"2","key":"10.1016\/j.molimm.2026.05.013_bib33","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20050648","article-title":"The immune paradox of sarcoidosis and regulatory T cells","volume":"203","author":"Miyara","year":"2006","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.molimm.2026.05.013_bib34","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","article-title":"Functional Delineation and Differentiation Dynamics of Human CD4(+) T Cells Expressing the FoxP3 Transcription Factor","volume":"30","author":"Miyara","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.molimm.2026.05.013_bib35","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-physiol-022516-034339","article-title":"Macrophage Polarization","volume":"79","author":"Murray","year":"2017","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.molimm.2026.05.013_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.738481","article-title":"Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis In Vivo and Baseline Signaling Profile Associates With Treatment Response","volume":"12","author":"Palmroth","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.molimm.2026.05.013_bib37","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.chest.2017.11.030","article-title":"The Pathogenesis of Pulmonary Sarcoidosis and Implications for Treatment","volume":"153","author":"Patterson","year":"2018","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.molimm.2026.05.013_bib38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1046\/j.1365-2249.2000.01365.x","article-title":"Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4(+) and CD8(+) T cells","volume":"122","author":"Prasse","year":"2000","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2026.05.013_bib39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1189\/jlb.0609378","article-title":"Differential polarization of alveolar macrophages and bone marrow-derived monocytes following chemically and pathogen-induced chronic lung inflammation","volume":"88","author":"Redente","year":"2010","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.molimm.2026.05.013_bib40","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3389\/fimmu.2018.01625","article-title":"Expanded Regulatory T Cells Induce Alternatively Activated Monocytes With a Reduced Capacity to Expand T Helper-17 Cells","volume":"9","author":"Romano","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.molimm.2026.05.013_bib41","first-page":"125","article-title":"HLA and environmental interactions in sarcoidosis","volume":"25","author":"Rossman","year":"2008","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"issue":"1","key":"10.1016\/j.molimm.2026.05.013_bib42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/MOH.0000000000000301","article-title":"Mechanism of granuloma formation in sarcoidosis","volume":"24","author":"Sakthivel","year":"2017","journal-title":"Curr. Opin. Hematol."},{"issue":"1","key":"10.1016\/j.molimm.2026.05.013_bib43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1021\/acsomega.9b02800","article-title":"Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases","volume":"5","author":"Sanachai","year":"2020","journal-title":"Acs Omega"},{"issue":"28","key":"10.1016\/j.molimm.2026.05.013_bib44","doi-asserted-by":"crossref","first-page":"20059","DOI":"10.1074\/jbc.R700016200","article-title":"JAK-STAT signaling: From interferons to cytokines","volume":"282","author":"Schindler","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.molimm.2026.05.013_bib45","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1046\/j.1365-2249.1997.4001304.x","article-title":"Jak3 activation in human lymphocyte precursor cells","volume":"108","author":"Sharfe","year":"1997","journal-title":"Clin. Exp. Immunol."},{"issue":"21","key":"10.1016\/j.molimm.2026.05.013_bib46","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1007\/s00018-015-1995-y","article-title":"Macrophage polarization in pathology","volume":"72","author":"Sica","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.molimm.2026.05.013_bib47","article-title":"Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed\/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)","author":"Spacek","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.molimm.2026.05.013_bib48","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2213-2600(18)30064-X","article-title":"Pulmonary sarcoidosis","volume":"6","author":"Spagnolo","year":"2018","journal-title":"Lancet Resp. Med."},{"issue":"7","key":"10.1016\/j.molimm.2026.05.013_bib49","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/00207454.2022.2151712","article-title":"Cognitive improving actions of tofacitinib in a mouse model of Alzheimer disease involving TNF-alpha, IL-6, PI3K-Akt and GSK-3beta signalling pathway","volume":"134","author":"Sui","year":"2024","journal-title":"Int. J. Neurosci."},{"issue":"2","key":"10.1016\/j.molimm.2026.05.013_bib50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1165\/rcmb.2009-0350OC","article-title":"Development of a Sarcoidosis Murine Lung Granuloma Model Using Mycobacterium Superoxide Dismutase A Peptide","volume":"44","author":"Swaisgood","year":"2011","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"issue":"2","key":"10.1016\/j.molimm.2026.05.013_bib51","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/rheumatology\/kead448","article-title":"Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases","volume":"63","author":"Taylor","year":"2024","journal-title":"Rheumatol. (Oxf. )"},{"issue":"6","key":"10.1016\/j.molimm.2026.05.013_bib52","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1055\/a-2716-5737","article-title":"Immunopathogenesis of Sarcoidosis","volume":"46","author":"Vagts","year":"2025","journal-title":"Semin. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.molimm.2026.05.013_bib53","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1164\/ajrccm.163.1.9906071","article-title":"Analysis of intracellular cytokines in CD4(+) and CD8(+) lung and blood T cells in sarcoidosis","volume":"163","author":"Wahlstrom","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.molimm.2026.05.013_bib54","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1161\/CIRCRESAHA.115.303895","article-title":"Foxp(3+) CD4+ T Cells Improve Healing After Myocardial Infarction by Modulating Monocyte\/Macrophage Differentiation","volume":"115","author":"Weirather","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.molimm.2026.05.013_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.molimm.2026.05.013_bib56","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/1756-185X.14441","article-title":"Tofacitinib for sarcoidosis, a new potential treatment","volume":"25","author":"Xu","year":"2022","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.molimm.2026.05.013_bib57","first-page":"1","article-title":"Therapeutic efficacy of tofacitinib in PDSAg-induced chronic experimental autoimmune uveitis in Wistar rat","author":"Yargi-Ozkocak","year":"2025","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"11","key":"10.1016\/j.molimm.2026.05.013_bib58","doi-asserted-by":"crossref","first-page":"19911","DOI":"10.1002\/jcp.28589","article-title":"Phosphoinositide 3-kinase\/protein kinase B inhibition restores regulatory T cell's function in pulmonary sarcoidosis","volume":"234","author":"Zhang","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"11","key":"10.1016\/j.molimm.2026.05.013_bib59","doi-asserted-by":"crossref","first-page":"19911","DOI":"10.1002\/jcp.28589","article-title":"Phosphoinositide 3-kinase\/protein kinase B inhibition restores regulatory T cell's function in pulmonary sarcoidosis","volume":"234","author":"Zhang","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.molimm.2026.05.013_bib60","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.intimp.2018.08.030","article-title":"Interleukin 33 ameliorates disturbance of regulatory T cells in pulmonary sarcoidosis","volume":"64","author":"Zhang","year":"2018","journal-title":"Int. Immunopharmacol."}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016158902600132X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016158902600132X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:02:40Z","timestamp":1783692160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016158902600132X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":60,"alternative-id":["S016158902600132X"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2026.05.013","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Restoration of Treg function and polarization of M2 macrophages by tofacitinib to alleviate sarcoidosis through the mediation of the JAK3\/STAT5 pathway","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2026.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}